StockMarketWire.com - Oncology, inflammation and infectious diseases focused Tiziana Life Sciences said it had been granted a patent in the US for an antibody that could be significant in the treatment of Covid-19.
The US Patent and Trademark Office had granted a patent for methods and use of fully-human monoclonal antibody (mAb; TZLS-501) for prophylactic and therapeutic intervention for human diseases.
The company initially entered into a world-wide exclusive license from Novimmune in 2017 and the license was currently maintained with Bristol Myers Squibb.
'The grant of this additional patent on TZLS-501 is of particular significance for the potential treatment of Covied-19 and other pulmonary diseases such as acute respiratory distress syndrome,' Tiziana Life Sciences.
The patent, No. 10,759,862, would be published on 1 September.
At 9:00am: [LON:TILS] Tiziana Life Sciences Plc share price was +7.5p at 157.5p
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.